Update in endocrinology

Annals of Internal Medicine

Volumn 129, Issue 9, 1998, Pages 719-725

  Schlechte, Janet A ^a   Kreisberg, Robert ^b  

^a UNIVERSITY OF IOWA   (United States)

^b Baptist Health Center   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BROMOCRIPTINE; CABERGOLINE; CALCIUM; CORTICOSTEROID; ETIDRONIC ACID; PREDNISONE; RALOXIFENE; SIMVASTATIN;

BONE DENSITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC APPROACH ROUTE; DRUG INDUCED DISEASE; ECHOGRAPHY; EYE DISEASE; GRAVES DISEASE; HEART INFARCTION; HUMAN; HYPERPARATHYROIDISM; OSTEOPOROSIS; PRIORITY JOURNAL; PROLACTINOMA; REVIEW; STROKE;

EID: 0032212805     PISSN: 00034819     EISSN: None     Source Type: Journal    
DOI: 10.7326/0003-4819-129-9-199811010-00008     Document Type: Review

References (4)

1. Walsh BW, Kuller LH, Wild RA, Paul S, Farmer M, Lawrence JB, et al. Effects of raloxifene on serum lipids and coagulation factors in healthy post-menopausal women. JAMA. 1998;279:1445-51.
2. Schneider AB, Gierlowski T, Shore-Freedman E, Stovall M, Ron E, Lubin J. Dose-response relationships for radiation-induced hyperparathyroidism. J Clin Endocrinol Metab. 1995;80:254-7.
3. Fujiwara S, Sposto R, Ezaki H, Akiba S, Neriishi K, Kodama K, et al. Hyperparathyroidism among atomic bomb survivors in Hiroshima. Radiat Res. 1992;130:372-8.
4. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S). Scandinavian Simvastatin Survival Study Group. Lancet. 1994;344:1383-9.